Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2U4RX
|
|||
| Drug Name |
S109
|
|||
| Synonyms |
oxapium iodide; 6577-41-9; Cyclonium; Cyclonium iodide; UNII-682380CG4N; SH 100; 682380CG4N; DSSTox_CID_26925; DSSTox_RID_82021; DSSTox_GSID_46925; Esperan; Oxapii iodidum; Ciclonium iodide; Iodure d'oxapium; Ioduro de oxapio; 1-[(2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl]-1-methylpiperidin-1-ium;iodide; CAS-6577-41-9; NCGC00181356-01; Oxapium iodide [INN:JAN]; Oxapii iodidum [INN-Latin]; C22H34INO2; Iodure d'oxapium [INN-French]; Ioduro de oxapio [INN-Spanish]; ANC 113; Espalexan (TN); Oxapium iodide (JP17/INN); SCHEMBL1316687; CHEMBL2107009; DTXSID6046925; s109; Tox21_112814; 2-Cyclohexyl-2-phenyl-4-piperidinomethyl-dioxolane-1,3 methiodide; AC-669; AKOS015969034; Tox21_112814_1; VA11456; N-Methyl-N-(2-cyclohexyl-2-phenyl-1,3 dioxolan-4-yl-methyl)-piperidinium iodide; NCGC00181356-02; DB-080725; FT-0656107; D01815; Q10859610; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidin-1-ium iodide; 1-((2-Cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methylpiperidinium iodide; Piperidinium, 1-((2-cyclohexyl-2-phenyl-1,3-dioxolan-4-yl)methyl)-1-methyl-, iodide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H34INO2
|
|||
| Canonical SMILES |
C[N+]1(CCCCC1)CC2COC(O2)(C3CCCCC3)C4=CC=CC=C4.[I-]
|
|||
| InChI |
1S/C22H34NO2.HI/c1-23(15-9-4-10-16-23)17-21-18-24-22(25-21,19-11-5-2-6-12-19)20-13-7-3-8-14-20;/h2,5-6,11-12,20-21H,3-4,7-10,13-18H2,1H3;1H/q+1;/p-1
|
|||
| InChIKey |
YHEWVHONOOWLMW-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 6577-41-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. Korean J Physiol Pharmacol. 2016 Mar;20(2):161-8. | |||
| REF 2 | Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.